生物工程角膜移植治疗感染性角膜炎

目的：观察生物工程角膜移植治疗感染性角膜炎的疗效，评价其临床应用价值和意义。

方法：对我院35例35眼需要进行手术治疗的感染性角膜炎患者分为3组：观察组15例，使用生物工程角膜施行板层角膜移植手术。对照组有两组：对照1组10例，使用保存人角膜施行板层角膜移植手术； 对照2组10例，实施自体结膜瓣遮盖手术。随访3～20mo，观察视力、感染控制情况以及角膜透明度。

结果：观察组15眼术后感染控制，视力不同程度提高，除1眼在随访中发生植片混浊外，其余14眼植片均维持基本透明。对照1组，除1眼病毒性角膜炎因病毒复发导致角膜混浊外，其余9眼角膜植片维持透明。对照2组，除1眼真菌性角膜溃疡感染加重，行眼内容物剜除术，其余角膜溃疡瘢痕修复。

结论：生物工程角膜是一种新型的人角膜替代材料，为解决逐年增长的角膜病患者与短缺的角膜供体之间的矛盾发挥了作用。

Bioengineered keratoplasty for infectious keratitis

AIM: To observe the efficacy of bioengineered cornea in the lamellar keratoplasty treatment of infectious keratitis, and to evaluate the clinical value and significance.

METHODS: Totally 35 eyes in 35 patients with infectious keratitis requiring surgical treatment in our hospital were divided into three groups: the observation group(n=15)received lamellar keratoplasty with bioengineered cornea; the control group 1(n=10)received lamellar keratoplasty with conserved human cornea; the control group 2(n=10)received autogenous conjunctival flap covering for corneal ulcer. The vision, infection control and corneal transparency were observed lasting for 3-20mo.

RESULTS: In the observation group, corneal infection was controlled in 15 eyes after operation and except for 1 eye with cornea opacity during follow-up, the other 14 eyes remained basically transparent. In the control group 1, 9 corneal grafts were transparent, except for 1 eye of viral keratitis experienced corneal opacity because of virus recurrence. In the control group 2, corneal ulcer was scar recoveried in 9 eyes, except for 1 eye of aggravated fungal corneal ulcer infection with later removing of eye content.

CONCLUSION: Bioengineered cornea is a novel alternative material of human cornea, which plays a significant role in resolving the contradiction between the increasing keratopathy and donor cornea shortage.